A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in ...
Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...
Assistant Controller of Patents (C.A. (COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent ...
In transition-age childhood-onset growth hormone deficiency, growth hormone response to the glucagon stimulation test depends mainly on pituitary dysfunction severity, with BMI having minimal impact.
The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
Sun Pharma has received approval from the Drugs Controller General of India to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results